Compositions and methods for inhibiting growth of...

Details Compositions and methods for inhibiting growth of... Compositions and methods for inhibiting growth of...

2011-04-19

2011-04-19

Yu, Misook (Department: 1642)

Drug, bio-affecting and body treating compositions

Immunoglobulin, antiserum, antibody, or antibody fragment,...

C530S387100

Reexamination Certificate

active

07927590

ABSTRACT:
The present invention is in the fields of cell biology, immunology and oncology. The invention relates to the discovery that there is a relationship between the expression levels of the tumor suppressor gene smad4 (also known as dpc4) and integrin αvβ6, and the responsiveness of patient populations to αvβ6-active compounds and compositions (e.g., antibodies and other ligands that bind αvβ6), particularly in cancer cells from such patient populations, more particularly on carcinomas such as pancreatic carcinomas. The invention thus provides methods for determining the responsiveness of tumor cells (particularly those from pancreatic tumors) to such αvβ6-active compounds and compositions by examining the expression of αvβ6and smad4 by the tumor cells, as well as methods of diagnosis and treatment/prevention of tumor progression using ligands, including antibodies and small molecule drugs, that bind to integrin αvβ6on the surfaces of tumor cells and/or that block one or more components of the TGF-β pathway, particularly in smad4-deficient tumor cells.

REFERENCES:
patent: 5942417 (1999-08-01), Ni et al.
patent: 2004/0048312 (2004-03-01), Li et al.
patent: 2005/0255102 (2005-11-01), Violette et al.
William E. Paul, ed., 3rd ed. 1993, Fundamental Immunology, p. 242.
Kaiser (Science, 2006, 313, 1370).
Bodey et al, 2001, Expert Opinion Biological Therapy, 1(4): 603-617.
Bodey et al, 2000, Anticancer Res, 20: 2665-2676.
Mellman I, 2006, The Scientist, 20(1): 47-56.
Lee et al, 1999, J Immunol, 163: 6292-6300.
Stedman's medical dictionary, 25th ed, 1990, p. 1652-1653.
Redman, 2005, J Oral pathol Med, 34(1): 23-9.
Xue et al, 2001, Biochem Biophys Res Comm, 288: 610-618.
Sipos et al, 2004, Histopathology, 45: 226-236.
Iacobuzio-Donahue et al, 2004, Clin Cancer Res, 10: 1597-1604.
Watanabe et al, 1997, J Natl Cancer Institute, 89(7): 512-8, abstract only.
European Patent Offce, Communication enclosing European search report, EP application No. 07810296.9, dated Apr. 8, 2010 (5 pages).
Weinreb, P H et al., “Function-Blocking Integrin Alphavbeta6 Monoclonal Antibodies: Distinct Ligand-Mimetic and Nonligand-Mimetic Classes”, Journal of Biological Chemistry, American Society for Biochemistry and Molecular Biology, Inc., US, vol. 279, No. 17, Feb. 11, 2004, pp. 17875-17887, XP002405412, ISSN 0021-9258.
Kracklauer, M P et al, “TGF[beta]1 Signaling Via [alpha]V[beta]6 Integrin”, Molecular Cancer 20030807 GB , vol. 2, Aug. 7, 2003, XP002573605, ISSN: 1476-4598.
Subramanian et al., “Targeting Endogenous Transforming Growth Factor—Receptor Signaling in SMAD4-Deficient Human Pancreatic Carcinoma Cells Inhibits Their Invasive Phenotype” Cancer Res., vol. 64, No. 15, Aug. 1, 2004, pp. 5200-5211, XP08102563.
Thomas et al., “Alpha v beta 6 Integrin in Wound Heading and Cancer of the Oral Cavity”, J. Oral Pathol. Med., vol. 35, No. 1, Jan. 2006, pp. 1-10, XP008102570.

Affiliated with

Also associated with

Rating

Compositions and methods for inhibiting growth of... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Compositions and methods for inhibiting growth of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions and methods for inhibiting growth of... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2682838